4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.79 +1.70%

+$0.16 today

Market cap
$596.08M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.81M

Average 0.77M

FDMT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$66.71M, compared with -$46.22M a year earlier. Trailing-twelve-month EBITDA was -$163.43M.

Context

  • EBITDA amounted to 155.5% of revenue in FY2025, down 416501.3 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$235.14M (-77.5%) for the fiscal year ending Dec 2026, a slowdown from the +14.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$66.71M-638.6% QoQ
Last fiscal yearDec 2025
-$132.48M+14.1% YoY
LTMMar 2026
-$163.43M+3.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.3%-33.4%+10.9 pp
1 year+14.1%-77.5%-91.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(132.48M) USD
Year-over-year change
+14.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 EBITDA of -$163.43M is the 6th highest of the 8 companies compared; the peer median is -$95.72M.
  • Its year-over-year change of +3.9% is the 5th highest of 8, against a peer median of +6.4%.
  • EBITDA amounts to 185.2% of revenue for FDMT, versus a peer median of 505.0%.
FDMT Competitors Peer median
EBITDA for FDMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$73.43M +298.8%—505.0%
OCGNOcugen, Inc.LTM Mar 2026-$64.18M -19.1%—1437.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$85.19M +20.5%——
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M +32.5%—120.0%
QUREuniQure N.V.LTM Mar 2026-$129.14M +6.4%—713.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
SLDBSolid Biosciences Inc.LTM Mar 2026-$190.1M -38.9%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
Peer median (excluding FDMT) -$95.72M+6.4%—505.0%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.